Head of Formulation & Process Development
Almac Pharma Services
Michael graduated in Pharmacy from Sunderland School of Pharmacy and was awarded his PhD from The University of Nottingham. In 1994, he joined SmithKline Beecham Pharmaceuticals working in Pharmaceutical Development on solid oral dosage formulations across all phases of development from the discovery interface to technology transfer of large scale processes to the commercial production network. He developed formulations, authored regulatory submissions, manufactured clinical trials supplies and project managed and delivered on development projects with a team of formulation and analytical scientists.
In 2002 Michael moved to Laboratoires Fournier as the Head of Pharmaceutical Sciences, working on nano-particulate formulations and combination products. He had responsibility for the pharmaceutical development department and successfully commercialised a nano-particulate tablet dosage form for EU and US markets before the company was acquired by Solvay.
In 2006 Michael returned to GlaxoSmithKline as Technical Director working on the transfer of development projects in to commercial manufacture, with a particular focus on QbD applications and interactions with US, European and International regulatory agencies.
In 2010 he joined Almac Pharma Services and is currently the Head of Formulation & Process Development. He is responsible for all drug product development activities from Phase 1 through to Phase 3 and technical transfer to commercial production. His department covers development and GMP manufacture of solid oral dosage forms.